• Aquestive Therapeutics forecasts 2026 revenue of $46 million-$50 million in its November 3 outlook.
• Non-GAAP adjusted EBITDA loss is projected at $30 million-$35 million.
• Third-quarter cash totaled $90.3 million, down from $98.5 million in the second quarter.
• An October Libervant out-licensing deal generated $10 million upfront, with potential contingent milestone payments totaling $47.5 million.
• Anaphylm’s potential launch is targeted for the second quarter of 2027, subject to FDA approval; its review goal date is March 16.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aquestive Therapeutics Inc. published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.